Results 81 to 90 of about 46,383 (210)

Remdesivir in COVID‐19: A Focus on Pediatric Cardiac Patients

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
The coronavirus disease 2019 (COVID‐19) pandemic has presented a significant global health challenge that necessitated the immediate search for various therapeutic modalities. Remdesivir, an antiviral drug inhibiting RNA‐dependent RNA polymerase (RdRp), was among the most heavily used drugs against COVID‐19.
Dima Bsat, Dalia Safi, Mariam Arabi, Mamunur Rahman Malik   +3 more
wiley   +1 more source

Evolutionary Multi-Objective Design of SARS-CoV-2 Protease Inhibitor Candidates

, 2020
Computational drug design based on artificial intelligence is an emerging research area. At the time of writing this paper, the world suffers from an outbreak of the coronavirus SARS-CoV-2.
A Alhossary, CA Lipinski, CA Nicolaou, D Douguet, D Weininger, E van der Horst, E Zitzler, GR Bickerton, H Nguyen, HG Beyer, K Deb, L Zhang, N Brown, N Brown, O Trott, P Ertl, P Ertl, RF de Freitas, RV Devi, SCH Pegg, SS Kaplan, T Gaillard, T Krause, TT Wager, W Dai   +24 more
core   +1 more source

Treatment outcomes of patients on Second-line Antiretroviral Therapy in resource-limited settings: A Systematic Review and Meta-Analysis [PDF]

, 2012
A growing proportion of patients on antiretroviral therapy in resource-limited settings have switched to second-line regimens. We carried out a systematic review in order to summarize reported rates and reasons for virological failure among people on ...
Abouyannis, Andrew Boulle, Bhaskaran, Boulle, Boyd, Bunupuradah, Castelnuovo, Edward J. Mills, El-Khatib, Fernandez-Montero, Ferradini, Fox, Freeman, Gilks, Hamers, Hoen, Hosseinipour, Jahn, Kahn, Keiser, Kimmel, Levison, LHomme, Long, May Myat, Mills, Mills, Mills, Nathan Ford, Olawale Ajose, Orrell, Pasquet, Pujades-Rodriguez, Siddharth Mookerjee, Sigaloff, Siripassorn, van Zyl, van Zyl, Wallis, Wilson, Zhao   +40 more
core   +2 more sources

EBV+ and Kaposi’s Sarcoma Herpesvirus‐Associated Multicentric Castleman Disease in a Patient With HIV Infection: A Case Report

Case Reports in Infectious Diseases, Volume 2026, Issue 1, 2026.
Multicentric Castleman disease is a rare proliferative disease of lymphoid tissue. It has rarely been reported in Asian countries, particularly in HIV‐positive patients. Here, we report a case of Kaposi’s sarcoma herpesvirus‐associated Multicentric Castleman disease (KSHV‐MCD).
Mai-Yin Huang, Zhe Li, Wei Zhang, Hai-Yun Chen, Jun Liu, Chong-Xi Li, Priya Gusain   +6 more
wiley   +1 more source

The glucose transporter PfHT1 is an antimalarial target of the HIV protease inhibitor lopinavir [PDF]

, 2015
Malaria and HIV infection are coendemic in a large portion of the world and remain a major cause of morbidity and mortality. Growing resistance of Plasmodium species to existing therapies has increased the need for new therapeutic approaches.
Armstrong, Christopher, Heitmeier, Monique R, Hruz, Paul W, Kraft, Thomas E, Odom, Audrey R   +4 more
core   +2 more sources

Prevalence and Clinical Implications of HPV Infection in Oral Cavity and Oropharynx in HIV+ Men

International Journal of Dentistry, Volume 2026, Issue 1, 2026.
Introduction Human papillomavirus (HPV) is associated with several types of oral lesions (OLs), including oropharyngeal squamous cell carcinoma (SCC), especially in HIV‐positive individuals. Objectives To identify the prevalence and clinical implications of the alpha (α) and beta (β) genera of HPV in the oral cavity and oropharynx of HIV‐positive men ...
José Adán Vizcaíno-Reséndiz, Jaime F. Andrade-Villanueva, Luis Felipe Jave-Suárez, Tonatiuh Abimael Baltazar-Díaz, Felipe De Jesús Bustos-Rodríguez, Luis Eduardo Del Moral-Trinidad, Dana Alejandra Figueroa-González, Juan Carlos Vázquez-Limón, Ana Esther Mercado-González, Luz Alicia González-Hernández, Hannah Wesley   +10 more
wiley   +1 more source

Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort

Frontiers in Cellular and Infection Microbiology
BackgroundDrug repurposing has become a widely adopted strategy to minimise research time, costs, and associated risks. Combinations of protease inhibitors such as lopinavir and darunavir with ritonavir have been repurposed as treatments for COVID-19 ...
Dóra Paróczai, Dóra Paróczai, András Bikov, András Bikov, Andreea Blidaru, Emanuel Bobu, Ana Lascu, Ana Lascu, Cristian Ion Mot, Cristian Ion Mot, Stefan Mihaicuta, Stefan Mihaicuta, Stefan Frent, Stefan Frent   +13 more
doaj   +1 more source

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial

Trials, 2020
Objectives To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-critically ill SARS-CoV-2 ...
Justin T. Denholm, Joshua Davis, David Paterson, Jason Roberts, Susan Morpeth, Thomas Snelling, Dominica Zentner, Megan Rees, Matthew O’Sullivan, David Price, Asha Bowen, Steven Y. C. Tong, for the ASCOT Investigator Group   +12 more
doaj   +1 more source

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

British Journal of Clinical Pharmacology, Volume 91, Issue 12, Page 3471-3481, December 2025.
Aim Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).
Allan Kengo, Juan Eduardo Resendiz‐Galvan, Letisha Najjemba, Henry Mugerwa, Amedeo De Nicolò, Antonio D'Avolio, Shakir Atoyebi, Lubbe Wiesner, Elin M. Svensson, Catriona Waitt, Paolo Denti   +10 more
wiley   +1 more source

Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations [PDF]

Journal of Medical Biochemistry, 2020
Background: Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk ...
Stanković Biljana, Kotur Nikola, Gašić Vladimir, Klaassen Kristel, Ristivojević Bojan, Stojiljković Maja, Pavlović Sonja, Zukić Branka   +7 more
doaj